These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19124372)

  • 1. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial.
    Donohue JF; Hanania NA; Fogarty C; Campbell SC; Rinehart M; Denis-Mize K
    Ther Adv Respir Dis; 2008 Aug; 2(4):199-208. PubMed ID: 19124372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebulized formoterol fumarate: Dose selection and pharmacokinetics.
    Gross NJ; Kerwin E; Levine B; Kim KT; Denis-Mize K; Hamzavi M; Carpenter M; Rinehart M
    Pulm Pharmacol Ther; 2008 Oct; 21(5):818-23. PubMed ID: 18655841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
    Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
    Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
    Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
    Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients.
    Gross NJ; Nelson HS; Lapidus RJ; Dunn L; Lynn L; Rinehart M; Denis-Mize K;
    Respir Med; 2008 Feb; 102(2):189-97. PubMed ID: 18363201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD.
    Hanania NA; Sethi S; Koltun A; Ward JK; Spanton J; Ng D
    Int J Chron Obstruct Pulmon Dis; 2019; 14():117-127. PubMed ID: 30643398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease.
    Kharidia J; Fogarty CM; Laforce CF; Maier G; Hsu R; Dunnington KM; Curry L; Baumgartner RA; Hanrahan JP
    Pulm Pharmacol Ther; 2008 Aug; 21(4):657-62. PubMed ID: 18501650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease.
    Campbell SC; Criner GJ; Levine BE; Simon SJ; Smith JS; Orevillo CJ; Ziehmer BA
    Pulm Pharmacol Ther; 2007; 20(5):571-9. PubMed ID: 16911869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI.
    Sutherland ER; Brazinsky S; Feldman G; McGinty J; Tomlinson L; Denis-Mize K
    Curr Med Res Opin; 2009 Mar; 25(3):653-61. PubMed ID: 19232039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
    Molimard M; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():28-34. PubMed ID: 15915010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebulized formoterol: a review of clinical efficacy and safety in COPD.
    Gross NJ; Donohue JF
    Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():223-32. PubMed ID: 20714376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD.
    Quinn D; Seale JP; Reisner C; Fischer T; Golden M; Fernandez C; Darken P; St Rose E; Thomas M; Tardie G; Orevillo C
    Respir Med; 2014 Sep; 108(9):1327-35. PubMed ID: 25060541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
    Scicchitano R; Aalbers R; Ukena D; Manjra A; Fouquert L; Centanni S; Boulet LP; Naya IP; Hultquist C
    Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.